RGNX
RegenxbioยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
RGNX Profile
Regenxbio Inc.
A biotechnology company that develops gene therapies for treating rare genetic diseases
Biological Technology
07/16/2008
09/17/2015
NASDAQ Stock Exchange
353
12-31
Common stock
9804 Medical Center Drive
, Rockville
, MD 20850
--
Regenxbio Inc., was founded on July 16, 2008. The company is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus gene therapies. In AAV gene therapy, viral genes are removed from the AAV, a small non-pathogenic cold virus, to produce a biological delivery vector called a vector. The sequence of the therapeutic gene is then inserted to form a recombinant vector. The company's proprietary AAV gene delivery platform includes exclusive rights to over 100 new AAV vectors, including AAV7, AAV8, AAV9 and AAVrh 10. The company's mission is to transform the lives of patients from serious diseases with significant unmet medical needs to direct in vivo gene therapy products through development and commercialization, or in vivo, based on its NAV technology platform.
